ES2534744T3 - Plasmina modificada de forma recombinante - Google Patents
Plasmina modificada de forma recombinante Download PDFInfo
- Publication number
- ES2534744T3 ES2534744T3 ES10166134.6T ES10166134T ES2534744T3 ES 2534744 T3 ES2534744 T3 ES 2534744T3 ES 10166134 T ES10166134 T ES 10166134T ES 2534744 T3 ES2534744 T3 ES 2534744T3
- Authority
- ES
- Spain
- Prior art keywords
- domain
- polypeptide
- terminal
- serine protease
- activation site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940012957 plasmin Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 10
- 102000012479 Serine Proteases Human genes 0.000 abstract 6
- 108010022999 Serine Proteases Proteins 0.000 abstract 6
- 230000004913 activation Effects 0.000 abstract 6
- 210000004899 c-terminal region Anatomy 0.000 abstract 6
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 abstract 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
- 239000004472 Lysine Substances 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 102000013566 Plasminogen Human genes 0.000 abstract 1
- 108010051456 Plasminogen Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Polipéptido para la utilización como medicamento, en el que el polipéptido se selecciona de a) un polipéptido que tiene un único dominio kringle N-terminal que es, como mínimo, el 90% idéntico al dominio kringle 1 del plasminógeno humano nativo, y un dominio C-terminal que comprende un sitio de activación y un dominio serina proteasa, dicho dominio C-terminal es, como mínimo, el 90% idéntico al sitio de activación y al dominio serina proteasa del plasminógeno humano; en el que el polipéptido se une a lisina inmovilizada, o b) un polipéptido que tiene un único dominio kringle N-terminal homólogo al dominio kringle1 del plasminógenonativo; y un dominio C-terminal que comprende un sitio de activación y un dominio serina proteasa, dicho dominio C-terminal es homólogo al sitio de activación y al dominio serina proteasa del plasminógeno humano; en el que el polipéptido se une a lisina inmovilizada y en el que el polipéptido es SEQ ID NO: 2 con no más de 30 sustituciones de aminoácidos, o c) un polipéptido que tiene un único dominio kringleN-terminal homólogo al dominio kringle 1 del plasminógeno nativo; y un dominio C-terminal que comprende un sitio de activación y un dominio serina proteasa, dicho dominio C-terminal es homólogo al sitio de activación y al dominio serina proteasa del plasminógeno humano; en el que el polipéptido se une a lisina inmovilizada, y en el que el polipéptido es, como mínimo, el 90%, 95%, o 98% idéntico a la secuencia que se muestra en SEQ ID NO: 2.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56447204P | 2004-04-22 | 2004-04-22 | |
| US564472P | 2004-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2534744T3 true ES2534744T3 (es) | 2015-04-28 |
Family
ID=34982338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05737862T Expired - Lifetime ES2349555T3 (es) | 2004-04-22 | 2005-04-21 | Plasmina modificada recombinántemente. |
| ES10166134.6T Expired - Lifetime ES2534744T3 (es) | 2004-04-22 | 2005-04-21 | Plasmina modificada de forma recombinante |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05737862T Expired - Lifetime ES2349555T3 (es) | 2004-04-22 | 2005-04-21 | Plasmina modificada recombinántemente. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8034913B2 (es) |
| EP (2) | EP1740698B1 (es) |
| JP (1) | JP5026254B2 (es) |
| KR (1) | KR101161819B1 (es) |
| CN (2) | CN1961070A (es) |
| AT (1) | ATE476502T1 (es) |
| AU (1) | AU2005238464B2 (es) |
| BR (1) | BRPI0510063B8 (es) |
| CA (1) | CA2563675C (es) |
| CY (1) | CY1111650T1 (es) |
| DE (1) | DE602005022692D1 (es) |
| DK (1) | DK1740698T3 (es) |
| EA (1) | EA010784B1 (es) |
| ES (2) | ES2349555T3 (es) |
| HR (1) | HRP20100568T1 (es) |
| IL (1) | IL178343A (es) |
| MA (1) | MA28590B1 (es) |
| MX (1) | MXPA06012236A (es) |
| NO (1) | NO338542B1 (es) |
| NZ (1) | NZ550250A (es) |
| PL (2) | PL1740698T3 (es) |
| PT (2) | PT2246417E (es) |
| RS (1) | RS51623B (es) |
| SI (1) | SI1740698T1 (es) |
| TN (1) | TNSN06332A1 (es) |
| WO (1) | WO2005105990A2 (es) |
| ZA (1) | ZA200608498B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2394103C2 (ru) | 2004-02-11 | 2010-07-10 | Биолекс Терапьютикс, Инк. | Экспрессия плазминогена и микроплазминогена в ряске |
| NZ550250A (en) | 2004-04-22 | 2009-05-31 | Talecris Biotherapeutics Inc | Recombinantly modifed plasminogen |
| US8231869B2 (en) * | 2005-10-20 | 2012-07-31 | Grifols Therapeutics Inc. | Recombinant plasmin for opthalmic indications |
| KR100888022B1 (ko) * | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8Ｆｃ |
| JP5539896B2 (ja) * | 2007-11-29 | 2014-07-02 | グリフオルス・セラピユーテイクス・インコーポレーテツド | 組換え的に改変されたプラスミン |
| NZ589557A (en) | 2008-06-04 | 2012-08-31 | Talecris Biotherapeutics Inc | Immobilised streptokinase, method and kit for preparing plasmin |
| ES2552337T3 (es) | 2009-03-03 | 2015-11-27 | Grifols Therapeutics Inc. | Procedimientos para la preparación de plasminógeno |
| US9226953B2 (en) | 2009-07-10 | 2016-01-05 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| EP2480249B1 (en) | 2009-08-28 | 2015-01-28 | ThromboGenics N.V. | Plasmin for the treatment of filtration failure after trabeculectomy |
| RU2432397C2 (ru) * | 2009-11-24 | 2011-10-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА |
| RU2432396C2 (ru) * | 2009-11-24 | 2011-10-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА |
| ES2583082T3 (es) | 2011-01-05 | 2016-09-19 | Thrombogenics N.V. | Variantes de plasminógeno y plasmina |
| RU2604810C2 (ru) | 2011-08-12 | 2016-12-10 | Тромбодженикс Н.В. | Варианты плазминогена и плазмина |
| US10709771B2 (en) * | 2015-12-18 | 2020-07-14 | Talengen International Limited | Method for preventing or treating diabetic retinopathy |
| WO2018107690A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法 |
| CN108210902A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗脂肪肝的药物及其用途 |
| WO2018107703A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种促进胰岛β细胞损伤修复和减少胰岛纤维化的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| CA3182911A1 (en) * | 2020-05-11 | 2021-11-18 | Talengen International Limited | Method and drug for treating spinal muscular atrophy |
| JP2023550301A (ja) | 2020-11-25 | 2023-12-01 | グリフォルス・ワールドワイド・オペレーションズ・リミテッド | 創傷治癒 |
| US11964004B2 (en) * | 2021-03-31 | 2024-04-23 | Shenzhen Bay Laboratory | Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof |
| AU2023309803A1 (en) | 2022-07-22 | 2025-01-09 | Grifols Worldwide Operations Limited | Stable plasmin compositions for organ preservation and reconditioning |
| WO2025235230A1 (en) * | 2024-05-07 | 2025-11-13 | The Scripps Research Institute | Engineered plasmin molecules and related compositions for treating thrombosis |
| CN119331857B (zh) * | 2024-12-19 | 2025-05-16 | 南通大学 | 一种新型重组蛋白Plasminogen-CTM及应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US5149533A (en) * | 1987-06-04 | 1992-09-22 | Zymogenetics, Inc. | Modified t-PA with kringle-/replaced by another kringle |
| US4774087A (en) | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| DK0835939T3 (da) | 1990-06-28 | 2006-03-13 | Sanofi Aventis Deutschland | Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse |
| US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
| CN1163619C (zh) | 1996-01-23 | 2004-08-25 | 佳根基因组学公司 | 测定核酸分子序列的方法和组合物 |
| US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| JPH10158300A (ja) | 1996-11-28 | 1998-06-16 | Suzuki Motor Corp | 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法 |
| EP1000176A1 (en) | 1997-07-22 | 2000-05-17 | Rapigene, Inc. | Computer method and system for correlating sequencing data by ms |
| US6538103B1 (en) | 1998-07-14 | 2003-03-25 | Bristol--Myers Squibb Company | Lysine binding fragments of angiostatin |
| DE69934595T2 (de) | 1998-09-29 | 2007-10-04 | Leuven Research & Development V.Z.W. | Verwendung von verbindungen,die alpha2-antiplasmin in vivo reduzieren,zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle |
| US6969515B2 (en) | 1999-11-13 | 2005-11-29 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US6355243B1 (en) | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| AU2001275091A1 (en) | 2000-06-02 | 2001-12-17 | Blue Heron Biotechnology, Inc. | Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides |
| ATE378413T1 (de) | 2000-12-21 | 2007-11-15 | Thromb X N V | Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle |
| AU2002357249A1 (en) | 2001-12-13 | 2003-07-09 | Blue Heron Biotechnology, Inc. | Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins |
| US20050124036A1 (en) | 2002-02-06 | 2005-06-09 | Rudy Susilo | Method for producing recombinant proteins in micro-organisms |
| US7776026B2 (en) | 2002-02-06 | 2010-08-17 | Nuvue Technologies, Inc. | Method for vitreous liquefaction |
| GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| NZ550250A (en) | 2004-04-22 | 2009-05-31 | Talecris Biotherapeutics Inc | Recombinantly modifed plasminogen |
| US8231869B2 (en) | 2005-10-20 | 2012-07-31 | Grifols Therapeutics Inc. | Recombinant plasmin for opthalmic indications |
| JP5539896B2 (ja) | 2007-11-29 | 2014-07-02 | グリフオルス・セラピユーテイクス・インコーポレーテツド | 組換え的に改変されたプラスミン |
-
2005
- 2005-04-21 NZ NZ550250A patent/NZ550250A/en not_active IP Right Cessation
- 2005-04-21 MX MXPA06012236A patent/MXPA06012236A/es active IP Right Grant
- 2005-04-21 CN CNA2005800155389A patent/CN1961070A/zh active Pending
- 2005-04-21 PT PT101661346T patent/PT2246417E/pt unknown
- 2005-04-21 PT PT05737862T patent/PT1740698E/pt unknown
- 2005-04-21 CA CA2563675A patent/CA2563675C/en not_active Expired - Lifetime
- 2005-04-21 WO PCT/US2005/013562 patent/WO2005105990A2/en not_active Ceased
- 2005-04-21 US US11/568,023 patent/US8034913B2/en not_active Expired - Fee Related
- 2005-04-21 AU AU2005238464A patent/AU2005238464B2/en not_active Ceased
- 2005-04-21 EP EP05737862A patent/EP1740698B1/en not_active Expired - Lifetime
- 2005-04-21 RS RS20100473A patent/RS51623B/sr unknown
- 2005-04-21 PL PL05737862T patent/PL1740698T3/pl unknown
- 2005-04-21 HR HR20100568T patent/HRP20100568T1/hr unknown
- 2005-04-21 KR KR1020067024427A patent/KR101161819B1/ko not_active Expired - Fee Related
- 2005-04-21 ES ES05737862T patent/ES2349555T3/es not_active Expired - Lifetime
- 2005-04-21 JP JP2007509616A patent/JP5026254B2/ja not_active Expired - Fee Related
- 2005-04-21 PL PL10166134T patent/PL2246417T3/pl unknown
- 2005-04-21 AT AT05737862T patent/ATE476502T1/de active
- 2005-04-21 EA EA200601950A patent/EA010784B1/ru not_active IP Right Cessation
- 2005-04-21 DK DK05737862.2T patent/DK1740698T3/da active
- 2005-04-21 CN CN2012101142890A patent/CN102660564B/zh not_active Expired - Fee Related
- 2005-04-21 EP EP10166134.6A patent/EP2246417B1/en not_active Expired - Lifetime
- 2005-04-21 BR BRPI0510063A patent/BRPI0510063B8/pt not_active IP Right Cessation
- 2005-04-21 SI SI200531131T patent/SI1740698T1/sl unknown
- 2005-04-21 DE DE602005022692T patent/DE602005022692D1/de not_active Expired - Lifetime
- 2005-04-21 ES ES10166134.6T patent/ES2534744T3/es not_active Expired - Lifetime
-
2006
- 2006-09-27 IL IL178343A patent/IL178343A/en active IP Right Grant
- 2006-10-11 ZA ZA200608498A patent/ZA200608498B/en unknown
- 2006-10-13 TN TNP2006000332A patent/TNSN06332A1/en unknown
- 2006-11-03 NO NO20065050A patent/NO338542B1/no not_active IP Right Cessation
- 2006-11-20 MA MA29466A patent/MA28590B1/fr unknown
-
2010
- 2010-10-18 CY CY20101100930T patent/CY1111650T1/el unknown
-
2011
- 2011-09-01 US US13/223,373 patent/US8420079B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2534744T3 (es) | Plasmina modificada de forma recombinante | |
| ES2534040T3 (es) | Plasmina modificada de forma recombinante | |
| ES2512141T3 (es) | Análogo peptídico de oxintomodulina | |
| ES2541217T3 (es) | Diferenciación de células madre mesenquimales | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| PE20171111A1 (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| UY30984A1 (es) | Proteinas de fusion de formula m-a para degradar péptidos beta amiloides, composiciones en base a ella, preparacion y aplicaciones. | |
| AR064032A1 (es) | Usos terapeuticos de polipeptidos heterologos il-17a/f | |
| CL2012001686A1 (es) | Analogo peptidico de oxintomodulina, en donde el aminoacido c-terminal es opcionalmente amidado; composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad. | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| BRPI0606612A2 (pt) | expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto | |
| CO2022008004A2 (es) | Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| PE20200514A1 (es) | Compuestos de mic-1 y usos de estos | |
| DE602005008071D1 (de) | C-terminale modifikation von polypeptiden | |
| BRPI0715331B8 (pt) | polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo | |
| EA201590431A1 (ru) | Пшеница с новыми аллелями rht-b1 | |
| EP4541810A3 (en) | Compounds for inducing tissue regeneration and uses thereof | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| NZ706202A (en) | Peptide antagonists of the vasopressin-2 receptor | |
| BRPI0508916A (pt) | polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os | |
| MX2016002556A (es) | Métodos y composiciones para el tratamiento de patologías del tejido de cartílago y disco. | |
| MX2025005121A (es) | Inhibidores de ccr2 y metodos de uso | |
| PL447134A1 (pl) | Aktywatory ludzkiego proteasomu 20S | |
| BRPI0621280A8 (pt) | Polipeptídeo tendo atividade esterase e esterase recombinante e seus usos |